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In the original version, the second paragraph
(last sentence) of the section ‘‘Efficacy of
Secukinumab in Patient Subgroups’’ under
heading FUTURE 1 AND FUTURE 2, a value is
incorrect. The correct sentence should read as:
The Week 52 observed data were 62.1% for
secukinumab 300 mg, 48.3% for secukinumab
150 mg, and 63.2% for secukinumab 75 mg
(Fig. 12b).
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